Han Wei, Wang Yutao, Fan Jingli, Wang Chunlei
Department of Pharmacy, Central Hospital of Zibo Mining Group Limited Liability Company, Zibo, China.
Shandong Institute of Prevention and Control for Endemic Disease, Thyroid Disease Prevention and Control Center, Jinan, China,
Onco Targets Ther. 2018 Nov 27;11:8359-8369. doi: 10.2147/OTT.S177601. eCollection 2018.
Numerous studies have been performed to investigate the association between promoter hypermethylation and bladder cancer risk. Nevertheless, the conclusion was uncertain due to small sample size, different ethnicities, and tumor subtype. Hence, to accurately assess the effect of promoter hypermethylation on the risk of bladder cancer, we performed the meta-analysis.
We retrieved the relevant literatures from electronic databases such as PubMed, Web of Science, Wanfang, Vapp, and CNKI (Chinese National Knowledge Infrastructure). 95% CI and OR were calculated to evaluate the associations of promoter hypermethylation with risk and clinical features of bladder cancer. Heterogeneity among studies was assessed with test and statistic. In addition, the diagnostic sensitivity, specificity, and area under the curve (AUC) value of APC hypermethylation for bladder cancer were calculated.
In total, 14 articles with 531 controls and 1,293 cases were included to assess the associations of promoter hypermethylation with the risk and clinical characteristics of bladder cancer. The significant association between promoter hypermethylation and bladder cancer risk was detected (OR =17.01, CI =7.40-39.07). Furthermore, the results revealed that promoter hypermethylation was significantly correlated with the grade of bladder tumor (pTNM stage: OR =1.84, CI =0.87-3.93; grade: OR =4.11, CI =1.62-10.43). According to the results of diagnostic evaluation, the diagnostic sensitivity, specificity, and AUC value of APC hypermethylation for bladder cancer risk were 0.52 (95% CI =0.41-0.63), 0.98 (95% CI =0.90-1.00), and 0.80 (95% CI =0.76-0.83), respectively.
This meta-analysis revealed that promoter hypermethylation was a risk factor for bladder cancer risk. In addition, promoter hypermethylation was significantly associated with the grade of bladder cancer. APC hypermethylation might be a useful biomarker for the clinical diagnosis of bladder cancer.
已开展大量研究以探究启动子高甲基化与膀胱癌风险之间的关联。然而，由于样本量小、种族不同以及肿瘤亚型各异，结论并不确定。因此，为准确评估启动子高甲基化对膀胱癌风险的影响，我们进行了荟萃分析。
我们从电子数据库如PubMed、Web of Science、万方、维普和中国知网（中国国家知识基础设施）中检索相关文献。计算95%置信区间（CI）和比值比（OR）以评估启动子高甲基化与膀胱癌风险及临床特征之间的关联。采用检验和统计量评估研究间的异质性。此外，计算了APC高甲基化对膀胱癌的诊断敏感性、特异性和曲线下面积（AUC）值。
总共纳入14篇文章，其中有531名对照和1293例病例，以评估启动子高甲基化与膀胱癌风险及临床特征之间的关联。检测到启动子高甲基化与膀胱癌风险之间存在显著关联（OR = 17.01，CI = 7.40 - 39.07）。此外，结果显示启动子高甲基化与膀胱肿瘤分级显著相关（pTNM分期：OR = 1.84，CI = 0.87 - 3.93；分级：OR = 4.11，CI = 1.62 - 10.43）。根据诊断评估结果，APC高甲基化对膀胱癌风险的诊断敏感性、特异性和AUC值分别为0.52（95% CI = 0.41 - 0.63）、0.98（95% CI = 0.90 - 1.00）和0.80（95% CI = 0.76 - 0.83）。
这项荟萃分析表明，启动子高甲基化是膀胱癌风险的一个危险因素。此外，启动子高甲基化与膀胱癌分级显著相关。APC高甲基化可能是膀胱癌临床诊断的一个有用生物标志物。
